Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term vinblastine. Found 19 abstracts

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group. Cancer. 2004 Apr;100(8):1639-45.
Haas NB, Giantonio BJ, Litwin S, Minniti CJ, Fox S, Yeslow G, Reilly R, Nahum K, Greenberg R, Halbherr T, Hudes GR. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma - A phase II trial of the fox chase network. Cancer. 2003 Nov;98(9):1837-41.
Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Phase II study of dolastatin-10 in patients with hormone- refractory metastatic prostate adenocarcinoma. Clinical Cancer Research. 2000 Nov;6(11):4205-8.
Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology. 1998 Aug;25(4):2-10.
Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. British Journal of Cancer. 1998 Feb;77(4):562-6.
Ranganathan S, Dexter DW, Benetatos CA, Hudes GR. Cloning and sequencing of human beta(III)-tubulin cDNA: induction of beta(III) isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochimica Et Biophysica Acta-Gene Structure and Expression. 1998 Jan 21;1395(2):237-45.
Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 1997 Sep;15(9):3156-63.
Ranganathan S, Salazar H, Benetatos CA, Hudes GR. Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. The Prostate. 1997 Mar;30(4):263-8.
Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of beta(III)- and beta(IVa)-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Research. 1996 Jun;56(11):2584-9.
Smith CD, Zhang XQ. Mechanism of action of cryptophycin - Interaction with the Vinca alkaloid domain of tubulin. Journal of Biological Chemistry. 1996 Mar 15;271(11):6192-8.
Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. Journal of Clinical Oncology. 1996 Jan;14(1):119-26.
Zhang XQ, Smith CD. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Molecular Pharmacology. 1996 Feb;49(2):288-94.
Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, McAleer C. Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate-Cancer. Seminars in Oncology. 1995 Oct;22(5):41-5.
Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R. Phase-I Study of Paclitaxel and Estramustine - Preliminary Activity in Hormone-Refractory Prostate-Cancer. Seminars in Oncology. 1995 Jun;22(3):6-11.
Smith CD, Zilfou JT, Zhang XQ, Hudes GR, Tew KD. Modulation of P-Glycoprotein Activity by Estramustine Is Limited by Binding to Plasma-Proteins. Cancer. 1995 May 15;75(10):2597-604.
Smith CD, Mooberry SL, Zhang XQ, Helt AM. A Sensitive Assay for Taxol and Other Microtubule-Stabilizing Agents. Cancer Letters. 1994 May 16;79(2):213-9.
Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD. P-Glycoprotein Binding and Modulation of the Multidrug- Resistant Phenotype by Estramustine. Journal of the National Cancer Institute. 1994 May 04;86(9):688-94.
Speicher LA, Laing N, Barone LR, Robbins JD, Seamon KB, Tew KD. Interaction of an Estramustine Photoaffinity Analog with Cytoskeletal Proteins in Prostate Carcinoma-Cells. Molecular Pharmacology. 1994 Nov;46(5):866-72.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term vinblastine

vinblastine tubulin estramustine taxol microtubule assembly invitro cancer doxorubicin binding monoclonal-antibody methotrexate invitro bovine brain trial cells cisplatin agents microtubule-associated proteins cooperative-oncology-group microtubule dynamics SURVIVAL carcinoma cell-lines du-145 antimicrotubule agents chemotherapy microtubules KeyWords Plus: proteins carcinoma drug resistance in-vitro phase-ii multidrug-resistance analogs 2 analogs & derivatives griseofulvin RESISTANCE multiple-drug quality of life Male molecular-weight Neoadjuvant Therapy resistant Female antimitotic agent apoptosis verapamil reverse multidrug-resistance gene CHEMOTHERAPY ifosfamide muscle invasion plasma proteins southwest-oncology-group progesterone 5-fluorouracil carboplatin alpha- prostate- drug Adult p-glycoprotein iii isotype TAMOXIFEN PLUS VINBLASTINE Middle Aged antimicrotubule activity surgery polymerization oncology- 80 and over Aged Cisplatin prostate cancer tubulin isotype Transitional Cell Carcinoma oral estramustine phosphate radiation-therapy beta-tubulin isotypes antimitotic drug phase-ii trial pathology suramin group mortality bladder cancer kinetic stabilization salvage cystectomy resistance colchicine Muscle Neoplasms REGIMEN cell-proliferation gemcitabine plus cisplatin beta-tubulin assembly Treatment Outcome modulation alpha-tubulin survival 4-dichlorobenzyl thiocyanate colchicine binding urothelial carcinoma Urinary Bladder Neoplasms statistics & numerical data METASTATIC BLADDER-CANCER Retrospective Studies leukemia group-b Methotrexate and cisplatin (M-VAC) regimen neoadjuvant expression mechanism Antineoplastic Combined Chemotherapy Protocols mitoxantrone radiotherapy etoposide Vinblastine transitional-cell-carcinoma inhibition carboplatin and paclitaxel (CP) regimen adenylyl cyclase pharmacology dynamic instability estramustine-phosphate differentiation Doxorubicin Neoplasm Invasiveness cancer cells secondary ANTIMITOTIC DRUG TRANSITIONAL-CELL-CARCINOMA antigen Aged structural features drug therapy REFRACTORY PROSTATE-CANCER Deoxycytidine therapeutic use antineoplastic agents proliferation dolastatin-10 administration & dosage Multicenter Studies as Topic drugs auristatin-pe colchicine-binding-site glucose transporter irradiation cytotoxicity COMBINATION
Last updated on Tuesday, April 03, 2018